ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/233910 |
Resumo: | Vaccination is the most effective public health intervention to prevent influenza infections, which are responsible for an important burden of respiratory illnesses and deaths each year. Currently, licensed influenza vaccines are mostly split inactivated, although in order to achieve higher efficacy rates, some influenza vaccines contain adjuvants. Although split-inactivated vaccines induce mostly humoral responses, tailoring mucosal and cellular immune responses is crucial for preventing influenza infections. Quillaja brasiliensis saponin-based adjuvants, including ISCOM-like nanoparticles formulated with the QB-90 saponin fraction (IQB90), have been studied in preclinical models for more than a decade and have been demonstrated to induce strong humoral and cellular immune responses towards several viral antigens. Herein, we demonstrate that a split-inactivated IQB90 adjuvanted influenza vaccine triggered a protective immune response, stronger than that induced by a commercial unadjuvanted vaccine, when applied either by the subcutaneous or the intranasal route. Moreover, we reveal that this novel adjuvant confers up to a ten-fold dose-sparing effect, which could be crucial for pandemic preparedness. Last but not least, we assessed the role of caspase-1/11 in the generation of the immune response triggered by the IQB90 adjuvanted influenza vaccine in a mouse model and found that the cellular-mediated immune response triggered by the IQB90-Flu relies, at least in part, on a mechanism involving the casp-1/11 pathway but not the humoral response elicited by this formulation. |
id |
UFRGS-2_170d14ae56a01f71d281e2d1e5b8259b |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/233910 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Rivera Patron, MarianaMoreno, MaríaBaz, MarianaRoehe, Paulo MichelCibulski, Samuel PauloSilveira, Fernando2022-01-07T04:33:29Z20212076-393Xhttp://hdl.handle.net/10183/233910001135263Vaccination is the most effective public health intervention to prevent influenza infections, which are responsible for an important burden of respiratory illnesses and deaths each year. Currently, licensed influenza vaccines are mostly split inactivated, although in order to achieve higher efficacy rates, some influenza vaccines contain adjuvants. Although split-inactivated vaccines induce mostly humoral responses, tailoring mucosal and cellular immune responses is crucial for preventing influenza infections. Quillaja brasiliensis saponin-based adjuvants, including ISCOM-like nanoparticles formulated with the QB-90 saponin fraction (IQB90), have been studied in preclinical models for more than a decade and have been demonstrated to induce strong humoral and cellular immune responses towards several viral antigens. Herein, we demonstrate that a split-inactivated IQB90 adjuvanted influenza vaccine triggered a protective immune response, stronger than that induced by a commercial unadjuvanted vaccine, when applied either by the subcutaneous or the intranasal route. Moreover, we reveal that this novel adjuvant confers up to a ten-fold dose-sparing effect, which could be crucial for pandemic preparedness. Last but not least, we assessed the role of caspase-1/11 in the generation of the immune response triggered by the IQB90 adjuvanted influenza vaccine in a mouse model and found that the cellular-mediated immune response triggered by the IQB90-Flu relies, at least in part, on a mechanism involving the casp-1/11 pathway but not the humoral response elicited by this formulation.application/pdfengVaccines. Basel. Vol. 9, no. 11 (Nov. 2021), 1350, 18 p.Vacinas contra influenzaQuillajaNanopartículasImunidadeAdjuvantes imunologicosAdjuvantsQuillaja brasiliensisISCOMsInfluenza virusDose-sparing effectISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccinesEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001135263.pdf.txt001135263.pdf.txtExtracted Texttext/plain71451http://www.lume.ufrgs.br/bitstream/10183/233910/2/001135263.pdf.txtbdd4e7c6752658d2eeded86edda770a5MD52ORIGINAL001135263.pdfTexto completo (inglês)application/pdf3387788http://www.lume.ufrgs.br/bitstream/10183/233910/1/001135263.pdf2ea210fb10694f68fe78fe3d0496788eMD5110183/2339102022-02-22 05:14:28.927227oai:www.lume.ufrgs.br:10183/233910Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2022-02-22T08:14:28Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines |
title |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines |
spellingShingle |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines Rivera Patron, Mariana Vacinas contra influenza Quillaja Nanopartículas Imunidade Adjuvantes imunologicos Adjuvants Quillaja brasiliensis ISCOMs Influenza virus Dose-sparing effect |
title_short |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines |
title_full |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines |
title_fullStr |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines |
title_full_unstemmed |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines |
title_sort |
ISCOM-like nanoparticles formulated with Quillaja brasiliensis Saponins are promising adjuvants for seasonal influenza vaccines |
author |
Rivera Patron, Mariana |
author_facet |
Rivera Patron, Mariana Moreno, María Baz, Mariana Roehe, Paulo Michel Cibulski, Samuel Paulo Silveira, Fernando |
author_role |
author |
author2 |
Moreno, María Baz, Mariana Roehe, Paulo Michel Cibulski, Samuel Paulo Silveira, Fernando |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Rivera Patron, Mariana Moreno, María Baz, Mariana Roehe, Paulo Michel Cibulski, Samuel Paulo Silveira, Fernando |
dc.subject.por.fl_str_mv |
Vacinas contra influenza Quillaja Nanopartículas Imunidade Adjuvantes imunologicos |
topic |
Vacinas contra influenza Quillaja Nanopartículas Imunidade Adjuvantes imunologicos Adjuvants Quillaja brasiliensis ISCOMs Influenza virus Dose-sparing effect |
dc.subject.eng.fl_str_mv |
Adjuvants Quillaja brasiliensis ISCOMs Influenza virus Dose-sparing effect |
description |
Vaccination is the most effective public health intervention to prevent influenza infections, which are responsible for an important burden of respiratory illnesses and deaths each year. Currently, licensed influenza vaccines are mostly split inactivated, although in order to achieve higher efficacy rates, some influenza vaccines contain adjuvants. Although split-inactivated vaccines induce mostly humoral responses, tailoring mucosal and cellular immune responses is crucial for preventing influenza infections. Quillaja brasiliensis saponin-based adjuvants, including ISCOM-like nanoparticles formulated with the QB-90 saponin fraction (IQB90), have been studied in preclinical models for more than a decade and have been demonstrated to induce strong humoral and cellular immune responses towards several viral antigens. Herein, we demonstrate that a split-inactivated IQB90 adjuvanted influenza vaccine triggered a protective immune response, stronger than that induced by a commercial unadjuvanted vaccine, when applied either by the subcutaneous or the intranasal route. Moreover, we reveal that this novel adjuvant confers up to a ten-fold dose-sparing effect, which could be crucial for pandemic preparedness. Last but not least, we assessed the role of caspase-1/11 in the generation of the immune response triggered by the IQB90 adjuvanted influenza vaccine in a mouse model and found that the cellular-mediated immune response triggered by the IQB90-Flu relies, at least in part, on a mechanism involving the casp-1/11 pathway but not the humoral response elicited by this formulation. |
publishDate |
2021 |
dc.date.issued.fl_str_mv |
2021 |
dc.date.accessioned.fl_str_mv |
2022-01-07T04:33:29Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/233910 |
dc.identifier.issn.pt_BR.fl_str_mv |
2076-393X |
dc.identifier.nrb.pt_BR.fl_str_mv |
001135263 |
identifier_str_mv |
2076-393X 001135263 |
url |
http://hdl.handle.net/10183/233910 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Vaccines. Basel. Vol. 9, no. 11 (Nov. 2021), 1350, 18 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/233910/2/001135263.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/233910/1/001135263.pdf |
bitstream.checksum.fl_str_mv |
bdd4e7c6752658d2eeded86edda770a5 2ea210fb10694f68fe78fe3d0496788e |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225048518819840 |